Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Oct
16
2023
Rite Aid Chapter 11 Bankruptcy Filing: Just What the Doctor Ordered Stark & Stark
Oct
14
2023
Registration Opens for Nano4Earth Roundtable Discussion on Capture of GHGs Bergeson & Campbell, P.C.
Oct
13
2023
McDermottPlus Check-Up: October 13, 2023 McDermott Will & Emery
Oct
13
2023
Alive and Well: Daubert Challenges Based on an Expert’s Lack of Qualifications Phillips Lytle LLP
Oct
13
2023
Governor Signs Bill Prohibiting Any Grocery Store Purchases Without Prior Written Notice To The Attorney General Allen Matkins Leck Gamble Mallory & Natsis LLP
Oct
12
2023
FDA Issues Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors [Podcast] K&L Gates
Oct
12
2023
California’s Transformational Single-Use Packaging EPR Law Moves Toward Implementation Beveridge & Diamond PC
Oct
12
2023
DEA Issues Second Temporary Rule Extending Controlled Substance Prescribing Flexibilities Through December 2024 Polsinelli PC
Oct
12
2023
Cell-Cultivated Meat Is Gaining Ground Womble Bond Dickinson (US) LLP
Oct
12
2023
DEA Further Extends Telemedicine Prescribing Flexibilities Dinsmore & Shohl LLP
Oct
12
2023
FDA Seeks Comment on Cosmetics Direct and Forms Regarding Registration of Cosmetic Product Facility and Cosmetic Product Listing Bergeson & Campbell, P.C.
Oct
11
2023
The U.S. Department of Labor Provides Guidance for Agricultural Employers on the PUMP Act Sheppard, Mullin, Richter & Hampton LLP
Oct
11
2023
EC Recommends Carrying Out Risk Assessment on Biotechnologies Bergeson & Campbell, P.C.
Oct
11
2023
FDA Updates Compliance Program for Infant Formula Keller and Heckman LLP
Oct
10
2023
EU Proposal for a Regulation on Packaging and Packaging Waste – the Highlights Keller and Heckman LLP
Oct
10
2023
CA Governor Newsom Signs Food Additive Ban into Law Keller and Heckman LLP
Oct
10
2023
Assessing Compliance with EU Food-Contact Regulations: Technical Considerations Keller and Heckman LLP
Oct
10
2023
California Governor Signs Bill Prohibiting Certain Food Additives Greenberg Traurig, LLP
Oct
10
2023
ACI Recognizes “Early Adopters” of Sustainable Feedstocks Initiative Bergeson & Campbell, P.C.
Oct
9
2023
At HLTH 2023: General Catalyst’s HATCo Introduces a Radically Ambitious and Transformative Model for Healthcare Sheppard, Mullin, Richter & Hampton LLP
Oct
9
2023
Notable New California Employment Bills Signed Into Law – Part 1 Barnes & Thornburg LLP
Oct
9
2023
Court Strikes Down HHS Rule on Copay Accumulators: Implications for Health Plans and PBMs Mintz
Oct
9
2023
California Bans Inquiries About Applicant Cannabis Use Jackson Lewis P.C.
Oct
9
2023
DEA Extends Telemedicine Flexibilities for Prescribing of Controlled Medications: Second Time is the Charm Foley & Lardner LLP
Oct
7
2023
The Tyranny of Large Numbers: Their Grip on s. 102 Inquiries Schwegman, Lundberg & Woessner, P.A.
Oct
6
2023
Federal Judge Rules Government Must Demonstrate “But-For” Causation for Anti-Kickback Statute Claims ArentFox Schiff LLP
Oct
6
2023
Laboratory-Developed Tests: FDA Publishes Highly Anticipated Proposed Rule McDermott Will & Emery
Oct
6
2023
CRS Report on Gene-Edited Plants Includes Issues Facing Congress Bergeson & Campbell, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins